The biggest change in dementia care this week is that Alzheimer's treatment moved from the infusion clinic to the living room. On July 13, 2026, the FDA approved LEQEMBI IQLIK (lecanemab-irmb), a once-weekly under-the-skin autoinjector, as the first at-home way to *start* anti-amyloid therapy for early Alzheimer's.
Lecanemab is an antibody that clears amyloid, a sticky protein that builds up in the brains of people with Alzheimer's. This matters because it removes a major barrier: the repeated intravenous (IV) infusions that once tied patients to a clinic. It arrives alongside a new agitation drug and cheaper blood-based diagnosis, so the practical picture for families is shifting on several fronts at once.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What actually changed this week
- Who qualifies, and who does not
- The safety trade-off families must weigh
- A separate approval for agitation
- Easier diagnosis is quietly widening the door
- Practical next steps for caregivers
- Frequently Asked Questions
What actually changed this week
The new option is an initiation dose, meaning it is how you begin treatment, not just maintain it. According to Eisai's approval announcement, the regimen is 500 mg weekly, given as two 250 mg injections that each take about 15 seconds. Until now, patients had to start on IV infusions.
Being able to begin with a subcutaneous (under-the-skin) autoinjector means a caregiver or patient may administer it at home after training, instead of traveling for infusions. Eisai expects U.S. availability in late August 2026 through specialty pharmacy. So the "this week" news is the approval; the "this month" change for real patients is the pharmacy rollout still a few weeks away.
Who qualifies, and who does not
This is not for everyone with memory loss. Per Biogen and Eisai, it is only for people with early Alzheimer's — mild cognitive impairment or mild dementia — and confirmed amyloid in the brain.
If a loved one is already past the mild stage, this specific option will not apply. That eligibility line is the first thing to check with a neurologist before hoping for a prescription.
- Confirmed amyloid is required, usually by PET scan, spinal fluid, or an approved blood test.
- It is not approved for moderate or late-stage Alzheimer's.
- After 18 months, patients may switch to a maintenance dose of 360 mg weekly.
The safety trade-off families must weigh
The convenience comes with a serious warning. Lecanemab carries a boxed warning — the FDA's strongest — for ARIA, or amyloid-related imaging abnormalities, which are episodes of brain swelling or small bleeds detected on MRI. Because of this, regular MRI monitoring is required during treatment.
Moving the injection home does not remove the need for scheduled brain scans and medical oversight. It is also important to set expectations. As Eisai's materials reflect, anti-amyloid antibodies slow decline modestly; they do not stop or reverse Alzheimer's. Families choosing this are buying time and function, not a cure.
A separate approval for agitation
The other notable shift addresses behavior, not memory. On April 30, 2026, Axsome Therapeutics announced FDA approval of Auvelity (dextromethorphan-bupropion) for agitation associated with Alzheimer's dementia. This is the first non-antipsychotic approved for this use, joining only Rexulti before it.
Agitation — restlessness, aggression, or pacing — is one of the hardest symptoms for caregivers, and antipsychotics carry their own risks in older adults. In the ACCORD trial, treated patients went significantly longer before agitation relapsed than those on placebo, with discontinuation rates comparable to placebo, as reported by Psychiatric Times. That gives clinicians a new tool that is not sedating in the way older drugs can be.
Easier diagnosis is quietly widening the door
None of these treatments work without confirming amyloid first, and that step is getting simpler. The FDA cleared the first Alzheimer's blood test in May 2025, and a second, the Roche/Lilly Elecsys pTau181 test, was cleared in October 2025 for primary-care use, according to Mayo Clinic. Primary-care clearance matters because it lets a regular doctor begin the workup, rather than requiring a specialist and a PET scan up front.
That shortens the path from "something feels off" to a confirmed diagnosis and, if appropriate, treatment. For context on where all this sits: two disease-modifying anti-amyloid drugs now hold full FDA approval — lecanemab (Leqembi, 2023) and donanemab (Kisunla, 2024). Both require confirmed amyloid and both carry ARIA risk.
Practical next steps for caregivers
If this week's news feels relevant to your family, a few concrete moves help. Keep a written list of current medications and recent scans to bring to that visit. The FY2026 NIH Alzheimer's budget report, presented around August 5, 2026, notes roughly 20 new drug candidates advanced into early trials — a reminder that today's options are a starting point, not the finish line.
- Ask the neurologist whether the patient is still in the mild/early stage with confirmed amyloid.
- If starting Leqembi, ask when the IQLIK autoinjector will be stocked at your specialty pharmacy and who will train you.
- Confirm the MRI monitoring schedule before the first dose, not after.
- If behavior is the main struggle, ask specifically about Auvelity versus current options.
Frequently Asked Questions
Can patients truly inject Leqembi at home now?
The autoinjector is approved for at-home use after training, but availability begins in late August 2026 through specialty pharmacy, so access is not instant.
Does the at-home version remove the need for brain scans?
No. MRI monitoring is still required because of the boxed warning for ARIA, brain swelling or bleeding that can occur on anti-amyloid therapy.
Is Auvelity a memory drug?
No. It treats agitation associated with Alzheimer's dementia, not memory loss, and it is the first non-antipsychotic approved for that symptom.
